Search
forLearn
5 / 801 resultslearn C 13-15 alkane
learn RH410
learn HT-B
learn KX-826
Research
5 / 1000+ results
research Involvement of the bulge region with decreased expression of hair follicle stem cell markers in senile female cases of alopecia areata
Decreased CD200 in hair follicles may cause immune issues in some alopecia areata cases.
research Divergent proliferation patterns of distinct human hair follicle epithelial progenitor niches in situ and their differential responsiveness to prostaglandin D2
Different human hair follicle stem cells grow at different rates and respond differently to a baldness-related compound.
research Faculty Opinions recommendation of Nonviral in situ green fluorescent protein labeling and culture of primary, adult human hair follicle epithelial progenitor cells.
Researchers developed a method to label and study human hair follicle stem cells using a fluorescent protein.
research Human keratinocytes derived from the bulge region of hair follicles are refractory to differentiation
Hair follicle cells resist turning into skin cells.
research In vitro identification of a stem cell population from canine hair follicle bulge region
Researchers found stem cells in dog hair follicles using specific markers.
Community Join
5 / 1000+ resultscommunity My Theory Of Androgenic Alopecia
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
community PP405 Won’t Work: Follicle Is Miniaturized, Fibrosed, And Missing Key Support Cells
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.
community SUBE3 for sale in the gray market?
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Looks like Kintor finished enrollment and dosing of phase 1 for gt20029 in China.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.